Metabolic syndrome risks of cardiovascular disease: differences between HIV-positive and HIV-negative?
Highly active antiretroviral therapy (HAART) has markedly prolonged life expectancy in patients infected with the human immunodeficiency virus (HIV). Use of HAART has been associated with development of a metabolic syndrome that may increase the risk of developing ischemic heart disease. The purpose of this review is to discuss the incidence and clinical manifestations of the metabolic syndrome in patients with HIV infection and contributing factors, as well as whether cardiovascular risk is disproportionately elevated in patients with HIV-associated metabolic syndrome.
Reeds
Dominic N
DN
Geriatrics and Nutritional Science and Center for Human Nutrition, Washington University School of Medicine, St Louis, MO 63110, USA. dreeds@im.wustl.edu
D002318:Cardiovascular Diseases / Q000453:epidemiology*; D018023:HIV Seronegativity; D006679:HIV Seropositivity / Q000150:complications*; D006801:Humans; D024821:Metabolic Syndrome / Q000453:epidemiology*; D017202:Myocardial Ischemia / Q000453:epidemiology; D012307:Risk Factors